{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:27:21Z","timestamp":1793834841746,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007730","name":"American Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.eururo.2013.04.001","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T04:46:33Z","timestamp":1365569193000},"page":"249-256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":376,"title":["OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.1016","volume":"64","author":[{"given":"Christopher","family":"Chapple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Dietrich","family":"Sievert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"MacDiarmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vik","family":"Khullar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Haag-Molkenteller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2013.04.001_bib0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/nau.20737","article-title":"Reviewing the ICS 2002 terminology report: the ongoing debate","volume":"28","author":"Abrams","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2013.04.001_bib0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2013.04.001_bib0015","first-page":"S90","article-title":"The total economic burden of overactive bladder in the United States: a disease-specific approach","volume":"15","author":"Onukwugha","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.eururo.2013.04.001_bib0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0025","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0030","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.04.001_bib0035","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2165\/00019053-199814050-00005","article-title":"Urge incontinence: quality of life and patients\u2019 valuation of symptom reduction","volume":"14","author":"O\u2019Conor","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.eururo.2013.04.001_bib0040","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0302-2838(03)00097-6","article-title":"Impact of urinary incontinence and overactive bladder on quality of life","volume":"43","author":"Chiaffarino","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0045","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","article-title":"The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study","volume":"101","author":"Coyne","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.04.001_bib0050","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00019053-199915040-00004","article-title":"Utility scores for chronic conditions in a community-dwelling population","volume":"15","author":"Mittmann","year":"1999","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2013.04.001_bib0055","first-page":"S98","article-title":"Impact of overactive bladder on work productivity in the United States: results from EpiLUTS","volume":"15","author":"Sexton","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.eururo.2013.04.001_bib0060","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2009.07.1325","article-title":"Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review","volume":"75","author":"Bartoli","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.04.001_bib0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/01443615.2011.649317","article-title":"An overview of treatment of overactive bladder syndrome in women","volume":"32","author":"Allahdin","year":"2012","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0075","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1742-1241.2010.02626.x","article-title":"Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature","volume":"65","author":"Sexton","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2013.04.001_bib0080","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00228-008-0600-9","article-title":"Persistence of antimuscarinic drug use","volume":"65","author":"Brostrom","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0085","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0090","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2013.04.001_bib0095","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2012.03.005","article-title":"OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial","volume":"62","author":"Fowler","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0155","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo-controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0105","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.urology.2008.05.033","article-title":"Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder","volume":"72","author":"Colman","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.04.001_bib0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000020026","article-title":"Cultural adaptation of a quality-of-life measure for urinary incontinence","volume":"36","author":"Patrick","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0115","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1471-0528.1997.tb11006.x","article-title":"A new questionnaire to assess the quality of life of urinary incontinent women","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1471-0528.2004.00129.x","article-title":"How much is enough and who says so?","volume":"111","author":"Kelleher","year":"2004","journal-title":"BJOG"},{"key":"10.1016\/j.eururo.2013.04.001_bib0125","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","article-title":"Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence","volume":"367","author":"Visco","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.04.001_bib0130","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.juro.2010.02.009","article-title":"Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature","volume":"183","author":"Anger","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0135","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","article-title":"Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA)","volume":"60","author":"Mangera","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0140","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","article-title":"Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity","volume":"49","author":"Apostolidis","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1442-2042.2011.02946.x","article-title":"Botulinum toxin type A for the treatment of lower urinary tract disorders","volume":"19","author":"Yokoyama","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2013.04.001_bib0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0002-9343(83)90073-6","article-title":"Measurement of pyuria and its relation to bacteriuria","volume":"75","author":"Stamm","year":"1983","journal-title":"Am J Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813003552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813003552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:02:58Z","timestamp":1759582978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283813003552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0302283813003552"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2013.04.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718006591.793477069","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718006591.793478312","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718006591.793482693","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2013.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}